About Minerva Neurosciences
Minerva Neurosciences (NASDAQ:NERV) focuses on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Its mission centers on addressing the unmet medical needs of patients suffering from neuropsychiatric diseases and other disorders. The company works on a variety of projects, including innovative treatments for schizophrenia, insomnia, and Parkinson’s disease, among others. Minerva aims to improve the lives of patients by pursuing the rigorous development of its therapeutic candidates, guided by scientific research and clinical studies. Through its dedicated efforts, Minerva strives to bring new, effective solutions to the healthcare market, aiding those affected by challenging CNS conditions.
Snapshot
Operations
Products and/or services of Minerva Neurosciences
- Roluperidone, a novel treatment for negative symptoms of schizophrenia aiming to improve social functioning and motivation.
- Brexanolone, for the treatment of postpartum depression, utilizing a proprietary IV formulation.
- MIN-117, targeting major depressive disorder (MDD) to reduce symptoms like anxiety and depression.
- Seltorexant (MIN-202), developed for insomnia and major depressive disorder, focusing on improving sleep patterns.
- MDD adjunctive treatment research, exploring novel compounds to enhance the effectiveness of existing depression therapies.
- Development of therapies for Parkinson’s disease, focusing on neuroprotective strategies to slow disease progression.
Minerva Neurosciences executive team
- Dr. Remy Luthringer Ph.D.Executive Chairman & CEO
- Mr. Geoffrey Robin Race F.C.M.A., M.B.A.President
- Mr. Frederick W. Ahlholm CPASenior VP, CFO & Secretary
- Mr. Joseph ReillySenior VP & COO
- Mr. William B. BoniVice President of Investor Relations & Corporate Communications
- Prof. Michael Davidson M.D.Chief Medical Officer